Gossamer Bio, Inc.
NMS: GOSSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Gossamer Bio, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get GOSS Z-Score →About Gossamer Bio, Inc.
Healthcare
Biotechnology
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
📊 Fundamental Analysis
Gossamer Bio, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 47.1% revenue growth, which is well above average for the Healthcare sector.
At a current price of $0.41, GOSS currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $0.32 - $3.87).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Revenue Growth
Excellent
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$96.11M
Trailing P/E
--
Forward P/E
-2.45
Beta (5Y)
2.16
52W High
$3.87
52W Low
$0.32
Avg Volume
16.42M
Day High
Day Low